Tumor necrosis factor is a survival and proliferation factor for human myeloma cells

European Cytokine Network

Volumn 10, Issue 1, 1999, Pages 65-70

  Jourdan, Michel ^a   Tarte, Karin ^a   Legouffe, Éric ^b   Brochier, Jean ^a   Rossi, Jean François ^b   Klein, Bernard ^a,c  

^a INSERM   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c HÔPITAL SAINT ELOI   (France)

Author keywords

Apoptosis; Interleukin 6; Multiple myeloma; Tumor necrosis factor

Indexed keywords

CYTOKINE ANTIBODY; GLYCOPROTEIN GP 130; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MYELOMA CELL; PLASMA CELL;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL DIVISION; CELL SURVIVAL; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032920168     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogiek B, Xiao H, Epstein J. 1994. Interleukin-6 prevents dexamethasone- induced myeloma cell death. Blood 84: 3063.
2. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T. 1988. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature 332: 83.
3. Klein B, Zhang X G, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R. 1989. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73: 517.
4. Klein B, Zhang X G, Lu Z Y, Bataille R. 1995. Interleukin-6 in human multiple myeloma. (Review) Blood 85: 863.
5. Bataille R, Harousseau J L. 1997. Multiple myeloma. (Review) N. Engl. J. Med. 336: 1657.
6. Zhang X G, Gaillard J P, Robillard N, Lu Z Y, Gu Z J, Jourdan M, Boiron J M, Bataille R, Klein B. 1994. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83: 3654.
7. Shimizu S, Yoshioka R, Hirose Y, Susumu S, Tachibana J, Konda S. 1989. Establishment of two interleukin-6 (B cell stimulatory factor-2/interferon-β2) dependent human bone marrow-derived myeloma cell lines. J. Exp. Med. 169: 339.
8. Westendorf J J, Ahmann G J, Greipp P R, Witzig T E, Lust J A, Jelinek D F. 1996. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 10: 866.
9. Borset M, Waage A, Brekke O L, Helseth E. 1994. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur. J. Haematol. 53: 31.
10. Baker S J, Reddy E P. 1996. Transducers of life and death: TNF receptor superfamily and associated proteins. (Review) Oncogene 12: 1.
11. Nagata S. 1997. Apoptosis by death factor. (Review) Cell 88: 355.
12. Malinin N L, Boldin M P, Kovalenko A V, Wallach D. 1997. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 385: 540.
13. Wang C Y, Mayo M W, Baldwin A S Jr. 1996. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784.
14. Van Antwerp D J, Martin S J, Kafri T, Green D R, Verma I M. 1996. Suppression of TNF-αlpha-induced apoptosis by NF-kappaB. Science 274: 787.
15. Beg A A, Baltimore D. 1996. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782.
16. Liautard J, Sun R X, Cotte N, Gaillard J P, Mani J C, Klein B, Brochier J. 1997. Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor. Cytokine 9: 233.
17. Collins M K, Marvel J, Malde P, Lopez-Rivas A. 1992. Inlerleukin-3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J. Exp. Med. 176: 1043.
18. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. 1995. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184: 39.
19. Jourdan M, Zhang X G, Portier M, Boiron J M, Bataille R, Klein B. 1991. IFN-alpha induced autocrine production of IL-6 in myeloma cell lines. J. Immunol. 147: 4402.
20. Helle M, Boeise L, Aarden L A. 1988. Functional discrimination between interleukin-6 and interleukin-1. Eur. J. Immunol. 18: 1535.
21. Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi J F, Wijdenes J, Brochier J, Klein B. 1998. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br. J. Haematol. 100: 637.
22. Kohase M, Henriksen-DeStefano D, May L T, Vilcek J, Sehgal P B. 1986. Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell 45: 659.
23. Van Damme J, Opdenakker G, Simpson R J, Rubira M R, Cayphas S, Vink A, Billiau A, van Snick J. 1987. Identification of the human 26-kD protein, interferon-beta2 (IFN-beta2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor. J. Exp. Med. 165: 914.
24. Hirano T. 1991. Interleukin-6 (IL-6) and its receptor: their role in plasma cell neoplasias. (Review) Int. J. Cell Cloning 9: 166.
25. Ogata A, Chauhan D, Teoh G, Treon S P, Urashima M, Schlossman R L, Anderson K C. 1997. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol. 159: 2212.
26. Guo D, Dunbar J D, Yang C H, Pfeffer L M, Donner D B. 1998. Induction of Jak/STAT signaling by activation of the type 1 TNF receptor. J. Immunol. 160: 2742.
27. Yang C H, Murti A, Pfeffer L M. 1998. STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proc. Natl. Acad. Sci. USA 95: 5568.
28. Lichtenstein A, Berenson J, Norman D, Chang M P, Carlile A. 1989. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74: 1266.
29. Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw A R, Lansdorp P M, Di Gugliemo R. 1989. Production of interleukin-1 by bone marrow myeloma cells. Blood 74: 380.
30. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. 1990. The role of interleukin-1 and tumor necrosis factor-α in human multiple myeloma. Br. J. Haematol. 74: 424.
31. Filella X, Blade J, Guillermo A L, Molina R, Rozman C, Ballesta A M. 1996. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect. Prev. 20: 52.
32. Blade J, Filella X, Montoto S, Bosch F, Molina R, Coca F, Lopez-Guillermo A, Cid J, Ballesta A M, Montserrat E. 1997. Clinical relevance of interleukine-6 and tumor necrosis factor alpha serum levels in monoclonal gammopathy of undetermined signifiance. Blood 90: 351a (abstract).